Compare Regeneron Pharmaceuticals Inc (REGN) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.87 (market cap $39.88B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.1× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| REGN | TTWO | |
|---|---|---|
Market Cap | $83.43B | $39.88B |
Sector | Health | Media |
52-Week High | $852.03 | $262.29 |
52-Week Low | $555.51 | $189.69 |
Enterprise Value | $78.14B | $41.00B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Take-Two Interactive trades at $213.29, down 0.65% amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -4.79% net margin and -$4.48B net loss for 2025, though recent earnings beats and GTA 6's November launch anticipation provide catalysts. Cash flow improved to $457M net inflow in 2025 from prior deficits, while debt-to-asset ratio rose to 39.87%.
Outlook hinges on GTA 6's execution, with 79% analyst buy ratings and $302.60 price target suggesting 42% upside. Risks include high valuation multiples (P/S 5.91, EV/EBITDA 32.78) and reliance on single-title success. Near-term volatility may persist pending Q3 earnings and preorder trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
